DK3481865T3 - Fc-mutanter med forbedret funktionel aktivitet - Google Patents

Fc-mutanter med forbedret funktionel aktivitet Download PDF

Info

Publication number
DK3481865T3
DK3481865T3 DK17739229.7T DK17739229T DK3481865T3 DK 3481865 T3 DK3481865 T3 DK 3481865T3 DK 17739229 T DK17739229 T DK 17739229T DK 3481865 T3 DK3481865 T3 DK 3481865T3
Authority
DK
Denmark
Prior art keywords
mutants
functional activity
enhanced functional
enhanced
activity
Prior art date
Application number
DK17739229.7T
Other languages
English (en)
Other versions
DK3481865T5 (da
Inventor
Céline Monnet
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Application granted granted Critical
Publication of DK3481865T3 publication Critical patent/DK3481865T3/da
Publication of DK3481865T5 publication Critical patent/DK3481865T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK17739229.7T 2016-07-06 2017-07-05 Fc-mutanter med forbedret funktionel aktivitet DK3481865T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1656463A FR3053688B1 (fr) 2016-07-06 2016-07-06 Mutants fc a activite fonctionnelle amelioree
PCT/EP2017/066791 WO2018007453A1 (fr) 2016-07-06 2017-07-05 Mutants fc a activite fonctionnelle amelioree

Publications (2)

Publication Number Publication Date
DK3481865T3 true DK3481865T3 (da) 2023-12-11
DK3481865T5 DK3481865T5 (da) 2024-09-02

Family

ID=57583168

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17739229.7T DK3481865T5 (da) 2016-07-06 2017-07-05 Fc-mutanter med forbedret funktionel aktivitet

Country Status (8)

Country Link
US (1) US11814438B2 (da)
EP (2) EP3481865B1 (da)
CA (1) CA3029971A1 (da)
DK (1) DK3481865T5 (da)
ES (1) ES2965076T3 (da)
FR (1) FR3053688B1 (da)
PL (1) PL3481865T3 (da)
WO (1) WO2018007453A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3075200B1 (fr) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
WO2019235426A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
CN115461363A (zh) * 2020-05-01 2022-12-09 诺华股份有限公司 免疫球蛋白变体
AU2021275632A1 (en) * 2020-05-20 2023-02-02 Janssen Biotech, Inc. Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
KR20250122541A (ko) 2022-10-25 2025-08-13 사이즈믹 테라퓨틱, 인코포레이티드. 변이체 IgG FC 폴리펩티드 및 그 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
WO2014030750A1 (ja) * 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Also Published As

Publication number Publication date
FR3053688B1 (fr) 2026-05-01
EP4273163A2 (fr) 2023-11-08
DK3481865T5 (da) 2024-09-02
US20190309085A1 (en) 2019-10-10
ES2965076T3 (es) 2024-04-11
CA3029971A1 (fr) 2018-01-11
EP3481865A1 (fr) 2019-05-15
FR3053688A1 (fr) 2018-01-12
WO2018007453A1 (fr) 2018-01-11
PL3481865T3 (pl) 2024-02-19
EP3481865B1 (fr) 2023-09-06
US11814438B2 (en) 2023-11-14
EP4273163A3 (fr) 2024-04-03

Similar Documents

Publication Publication Date Title
DK3292145T3 (da) Fc-mutanter med modificeret funktionel aktivitet
IL250320B (en) Compounds active toward bromodomains
LT3148579T (lt) Anti-gitr antikūnai ir jų panaudojimo būdai
LT3099717T (lt) Antikūno molekulės tim-3-čiam ir jų panaudojimas
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
DK2892246T3 (da) Hovedtelefoner med passage over hovedet
EP3285644C0 (en) DETECTION OF ACTIVITY IN PERIPHERAL NERVE
DK3167052T3 (da) P450-bm3-varianter med forbedret aktivitet
IL259202A (en) Modified immune cells and uses thereof
DK3105320T3 (da) Syntetisk nethinde
LT3337506T (lt) Deriniai ir jų panaudojimas
EP3227160C0 (en) HARNESS AND PULLING SET
DK3481865T3 (da) Fc-mutanter med forbedret funktionel aktivitet
DK3201222T3 (da) Rekombinasemutanter
DK3303243T3 (da) Spejl med forbedret holdbarhed
DK3430031T3 (da) Peptider med anti-kræftaktivitet
DK3247496T3 (da) Udsugningsapparat med reguleret udsugningsindretning
HUE052786T2 (hu) Diszlipidémia elleni aktivitással rendelkezõ étrendi kompozíció
DK3198099T3 (da) Møbelhængsel
ES2499118B2 (es) Quemador de biomasa y procedimiento de utilización
DK3297292T3 (da) Ørekop med fastgørelsesenhed
FR3026625B1 (fr) Structure pliable de meuble et meuble associe
HUE045174T2 (hu) Parenterális készítmények és alkalmazásuk
ES1106111Y (es) Estructura de montaje y ampliacion de mesas
TH1401001806B (th) เครื่องขัดผิว